Thousands of scientists and physicians are in New Orleans discussing the latest research and innovations in hematology at the American Society of Hematology’s 64th Annual Meeting.
CSL, which is supporting several educational sessions, shared new research data at the meeting.
ASH has more than 18,000 members in 100 countries and is the largest professional society for doctors and scientists. The meeting, which started Saturday and runs through December 13, will be both in-person and virtual with dozens of sessions, poster presentations, award lectures, workshops and exhibits.
CSL is a global biotech company that specializes in developing and manufacturing medicines for people who have rare and serious diseases. The company is sponsoring sessions at the ASH meeting on gene therapy and graft versus host disease, which affects recipients of organ transplants.
The annual meeting puts ASH’s mission into action by facilitating the exchange of scientific information and clinical results related to disorders affecting blood, bone marrow and the immunologic, hemostatic and vascular systems. The event also helps physicians and scientists form academic collaborations to generate new knowledge, ultimately benefiting patients.
